Aura Biosciences, Inc. (AURA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$7.56+2.58%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · AURA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
AURA — earnings miss
Dated 2026-08-11
Results of Operations and Financial Condition. On August 11, 2026, (the “Effective Date”), Aura Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exc…
Why it matters: Initial data will show how well bel-sar treats bladder cancer.
Watch forWe expect to see early clinical data by mid-2026.
Also watch forInitial data is not reported by mid-2026.
Why it matters: Trends in net loss will show financial health as Aura focuses on eye cancer.
Worry ifNet loss is lower than in past quarters. This shows better money management.
Less concerning ifNet loss increases or remains high, showing continued financial strain.
Why it matters: Interim data will show how well bel-sar works for bladder cancer.
Watch forInterim data shows strong responses in NMIBC patients treated with bel-sar.
Also watch forInterim data shows weak or no responses in NMIBC patients treated with bel-sar.
Why it matters: If the health care sector's revenue growth speeds up, it may help Aura's performance. This could improve investor sentiment.
Supportive ifHealth care sector revenue growth rises back toward 10% year over year.
Worry ifHealth care sector revenue growth continues to slow below current levels.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$202 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $523 loss on $10,000 · 5.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,124 loss on $10,000 · 31.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Finishing enrollment is key for bel-sar's chance at regulatory approval. It shows the company's progress in its main trial.
Supportive ifEnrollment will finish by mid-2026. This confirms the timeline set by management.
Worry ifEnrollment does not complete by mid-2026, indicating delays in the trial.
Why it matters: Finishing the restructuring will show if Aura can improve operations. They focus on eye cancer.
Supportive ifRestructuring is done with a clear focus on eye cancer and better efficiency.
Worry ifRestructuring efforts are delayed or do not bring the expected results.
Why it matters: A bigger net loss could show financial trouble and hurt investor trust.
Worry ifNet loss for Q3 2026 is reported below $45 million.
Less concerning ifNet loss exceeds $45 million, raising concerns about financial health.
Why it matters: The earnings report will show if Aura is moving toward profitability. Investors look for signs of improvement.
Watch forAura will share its next earnings date. They expect good news on revenue or costs.
Also watch forAura will share its next earnings date. They expect bad news or no change in losses.
Why it matters: Early data will help check how well bel-sar treats choroidal metastases. This could grow its market.
Watch forEarly data from the Phase 2 trial shows positive efficacy results.
Also watch forEarly data from the Phase 2 trial shows poor efficacy results.
Why it matters: News on the buyback program will show how management uses capital.
Supportive ifMore share buybacks may be announced or done after the recent buyback.
Worry ifNo new announcements or actions about the buyback program.
Why it matters: Finishing the restructuring will show how well Aura is using its resources. This could affect cash and efficiency.
Supportive ifRestructuring is done with a smaller workforce and better focus.
Worry ifRestructuring is late or causes more problems.
Why it matters: Topline data will show if bel-sar works for early choroidal melanoma. This could lead to new treatments.
Supportive ifTopline data shows good results for bel-sar in the CoMpass trial.
Worry ifTopline data shows no good results for bel-sar in the CoMpass trial.
Why it matters: Updates will provide insight into the progress of bel-sar in other ocular cancers. This could affect future growth and investment.
Watch forThere are good updates on how well bel-sar works in other eye cancer programs.
Also watch forBad updates or delays in the eye cancer programs.
Why it matters: Updates on cash runway will indicate financial health and ability to fund ongoing trials. This is crucial for investor confidence.
Watch forManagement says cash will last into 1H 2029 without more funding.
Also watch forManagement warns of possible cash shortages or need for more funding.